DE2836419A1 - Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer - Google Patents

Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer

Info

Publication number
DE2836419A1
DE2836419A1 DE19782836419 DE2836419A DE2836419A1 DE 2836419 A1 DE2836419 A1 DE 2836419A1 DE 19782836419 DE19782836419 DE 19782836419 DE 2836419 A DE2836419 A DE 2836419A DE 2836419 A1 DE2836419 A1 DE 2836419A1
Authority
DE
Germany
Prior art keywords
core
release
retard form
form according
prolonged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19782836419
Other languages
German (de)
Inventor
Dietrich Dr Arndts
Bernhard Dr Freund
Heribert Harwalik
Herbert Dr Stricker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CH Boehringer Sohn AG and Co KG
Original Assignee
CH Boehringer Sohn AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CH Boehringer Sohn AG and Co KG filed Critical CH Boehringer Sohn AG and Co KG
Priority to DE19782836419 priority Critical patent/DE2836419A1/en
Priority to DD79214300A priority patent/DD146547A5/en
Priority to FI792204A priority patent/FI792204A/en
Priority to SE7906119A priority patent/SE7906119L/en
Priority to NO792335A priority patent/NO792335L/en
Priority to BE0/196306A priority patent/BE877706A/en
Priority to DK296979A priority patent/DK296979A/en
Priority to GB7924504A priority patent/GB2025227B/en
Priority to GR59598A priority patent/GR71195B/el
Priority to LU81503A priority patent/LU81503A1/en
Priority to IT49752/79A priority patent/IT1116877B/en
Priority to NL7905484A priority patent/NL7905484A/en
Priority to PT69922A priority patent/PT69922A/en
Priority to ZA00793542A priority patent/ZA793542B/en
Priority to PL21711379A priority patent/PL217113A1/xx
Priority to IL57796A priority patent/IL57796A0/en
Priority to FR7918301A priority patent/FR2430766A1/en
Priority to CA331,894A priority patent/CA1126156A/en
Priority to AU48947/79A priority patent/AU4894779A/en
Publication of DE2836419A1 publication Critical patent/DE2836419A1/en
Priority to US06/273,643 priority patent/US4361546A/en
Priority to US06/409,131 priority patent/US4459279A/en
Priority to US06/604,830 priority patent/US4578264A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical prepn. in retard form comprises a core contg. >=1 active substance together with a carrier or excipient. The core is coated with a semipermeable coating of 20-90% water-insoluble film former (I) (e.g. ethyl cellulose) and 10-80% water-soluble polymer (II), e.g. PVP, PEG or methyl cellulose. The release of active substance is independent of pH in the body fluid over the whole period of its activity. The core pH may be reduced by inclusion of acidic material to reduce disintegration time. Dosage regimens are simplified, and initial very high blood levels may be avoided. The core may be in the form of a tablet. The coating pref. has the same permeability over its whole surface. The core may contain an organic food acid to reduce the disintegration time of the core, e.g. citric or tartaric acid is used. The coating may also contain up to 70% water insol. polymer e.g. cellulose acetate.

Description

Neue Chinidin-RetardformNew sustained-release form of quinidine

Die Erfindung betrifft eine neue Chiniain-etardforn, bei welcher in einer Gelatine-Kapsel unverzögerte sog.The invention relates to a new Chiniain-etardforn, in which in a gelatin capsule instantaneous so-called

Initial-Tabletten zusammen mit weiteren Tabletten verschiedener Verzögerungsstufen zu einer Einheit zusammengefaßt sind und welche dadurch gekennzeicnnez ist, daß die Retardtabletten eine unter Standardbedingungen aufgetragene Diffusionshülle bestimmter auf den Wirkstoff abgestimmter ZUsammensetzu1g und Dicke aufweisen sowie die Löslichkeit des Wirkstoffs durch den Zusatz saurer Stoffe verbessert wurde.Initial tablets together with other tablets of various delay levels are combined into a unit and which is characterized by the fact that the prolonged-release tablets have a diffusion shell applied under standard conditions have certain composition and thickness matched to the active substance and the solubility of the active ingredient was improved by the addition of acidic substances.

Die ideale orale Depotform muß ähnlich wirken wie eine intravenöse Dauerinfusion, d.h. sie muß (nach zunächst raschem Anstieg) für die gewünschte Wirkungsdauer des Medikamentes einen möglichst konstanten Blutspiegel (ein sog. "Plateau") aufrechterhalten.The ideal oral depot form must have a similar effect to an intravenous one Continuous infusion, i.e. it must (after initially rapid increase) for the desired duration of action Maintain a blood level of the drug that is as constant as possible (a so-called "plateau").

Die Annäherung an dieses Ideal wird in der Praxis durch die verschiedensten Faktoren erschwert, die (im Unterschied zur intravenösen Verabreichung) auf ein oral einzunehmendes Präparat während des Durchlaufens des agen-Darm-Trakts einwirken. Zu nennen sind hier beispielsweise der pH-Gradient, die Motilität, der Enzyingehalt sowie der Elektrolyt- und Wassergehalt des Magen-Darm-rakts.The approach to this ideal is in practice by the most diverse Factors that make it difficult (in contrast to intravenous administration) to a Oral preparation act while passing through the agen-intestinal tract. Examples include the pH gradient, motility, and enzyme content as well as the electrolyte and water content of the gastrointestinal tract.

Eine gute Methode, von diesen Einflußparametern möglichst unabhängig zu werden und Schwankungen in der FreiOabegeschwindigkeit möglichst auszugleichen, besteht darin, in einer Hartgelatine-Steckkapsel eine oder meHrere sog.A good method, as independent as possible from these influencing parameters and to compensate for fluctuations in the release speed as much as possible, consists in placing one or more so-called

Initialtabletten mit weiteren Tabletten,welche aufgrund unterschiedlicher Zusammensetzung und Diche der Diffusionshülle unterschiedliche rreigabegeschwindigkeiten aufweisen, zu einer Dosierungseinheit zusammenzufassen. Die annäherung an den idealen Ereigabeverlauf wird dabei wesentlich mitbestinuft von der stofflichen Zusammensetzung sowie der Dicke der Diffusionshülle, welche auf die Art des zu verzögernden Wirkstoffs abgestimmt sein müssen.Initial tablets with additional tablets, which are due to different Composition and density of the diffusion envelope different release rates have to be combined into a dosage unit. The approach to the ideal The course of the event becomes essential codetermination of the material Composition as well as the thickness of the diffusion envelope, which depends on the type of the Active ingredient must be matched.

Bei dem (meist als Sulfat zum Einsatz kommenden) Antiarrhythmicum Chinidin handelt es sich um eine relativ schlecht wasserlösliche Substanz.In the case of the antiarrhythmic (mostly used as sulfate) Quinidine is a relatively poorly water-soluble substance.

Es wurde nun gefunden, daß es gelingt, eine optimale Freigabekurve für den Wirkstoff Chinidin im Dosisbereich von 150-1500 mg zu erhalten, wenn man bei einer Retardform, welche aus Retardtabletten verschiedener Verzögerungsstufen sowie gegebenenfalls unverzögerten Tabletten in einer Kapsel besteht, die Retardtabletten mit einer Lackhülle aus 20-90 , vorzugsweise 40-70 % Äthylcellulose und 10-80 ,4, vorzugsweise 30-60 Só Polyäthylenglykol unter Standardbedingungen bis zu einer Hüllendicke von 5-30 5', bezogen auf das Gewicht der Preßlinge, überzieht. Hierbei erhalten die Retardtabletten höherer Verzögerungsstufen entsprechend dickere Hüllen als diejenigen niedriger Verzögerungsstufen.It has now been found that an optimal release curve is achieved for the active ingredient quinidine in the dose range of 150-1500 mg if one in the case of a sustained-release form, which consists of sustained-release tablets of various delay levels and, if necessary, immediate tablets in a capsule, the prolonged-release tablets with a coating of 20-90, preferably 40-70% ethyl cellulose and 10-80, 4, preferably 30-60 Só polyethylene glycol under standard conditions up to a shell thickness of 5-30 5 'based on the weight of the compacts. Received here the prolonged-release tablets of higher delay levels, correspondingly thicker shells than those lower delay levels.

Zweckmäßig ist es ferner, alle unverzögerten Initial-Tabletten leicht zerfallbar (z.B. unter Zusatz von Maisstärke und/oder mikrokristaliner Cellulose) herzustellen.It is also useful to lightly take all immediate initial tablets disintegrable (e.g. with the addition of corn starch and / or microcrystalline cellulose) to manufacture.

Wichtig ist ferner der Zusatz von sauren Stoffen (z.B.It is also important to add acidic substances (e.g.

organischen Genußsäuren) zu den Retardtabletten zwecks Verbesserung der Löslichkeit des Wirkstoffs im Inneren der Hülle.organic edible acids) to the prolonged-release tablets for the purpose of improvement the solubility of the active ingredient inside the shell.

Besonders günstige Ergebnisse (z.B. eine besonders geringe Standardabweichunb uer Hüllen-Permeabilität vom Mittelwert) ergeben sich, wenn bestimmte Herstellbedingungen stets konstant gehalten werden. Auf diese Weise ergibt sich ein reproduzierbarer Einbau des wasserlöslichen Polyäthylenglykols in die wasserunlösliche Äthylcellulose, was nach dem Herauslösen der ersteren zu einer gut reproduzierbaren Hüllenporosität führt.Particularly favorable results (e.g. a particularly low standard deviation outer shell permeability from the mean value) result when certain manufacturing conditions always be kept constant. This results in a reproducible Incorporation of the water-soluble polyethylene glycol into the water-insoluble ethyl cellulose, which after the removal of the former results in a well reproducible shell porosity leads.

Hierbei haben sich das Einhalten einer hohen Sprühgeschwindigkeit, erhöhte Sprühtemperatur sowie die Standardisierung des Wassergehalts in dem zum Auftragen der Hülle benützten Lösungsmittel als besonders vorteilhaft erwiesen.It is important to maintain a high spray speed, increased spray temperature as well as the standardization of the water content in the for Applying the shell used solvents proved to be particularly advantageous.

Eine besonders günstige Freigabekurve (d.h. rascnes Erreichen eines hohen Blutplasmaspiegels mit anschließender Plateaubildung) wird mit einer Retardform erreicht, wie sie in dem nachstehenden Beispiel beschrieben ist.A particularly favorable release curve (i.e. rapid achievement of a high blood plasma level with subsequent plateau formation) is with a sustained release form as described in the example below.

Durch die neue Form wird das Dosierungsschema des Arztes wesentlich vereinfacht. Ferner werden (durch Plasmaspiegel-Spitzen) leicht eintretende zu starke Effekte vermieden, was für ein Antiarrhythmicunl besonders wichtig ist.The new form makes the doctor's dosage regimen essential simplified. Furthermore (due to plasma level peaks), those that occur easily become too strong Effects avoided, which is particularly important for an antiarrhythmicunl.

Die neue Form eignet sich insbesondere auch für die Herstellung von Kombinationspräparaten des Chinidins, bei welchem der zusätzliche Wirkstoff z.B; in einer weiteren Initialtablette untergebracht werden kann.The new shape is particularly suitable for the production of Combination preparations of quinidine, in which the additional active ingredient e.g. can be accommodated in another initial tablet.

Das folgende Beispiel erläutert die Erfindung, ohne sie zu beschränken: Beispiel Chinidinsulfat-Retardform Die Herstellung der leicht zerfallenden Initial-Tabletten erfolgt durch Zusammenmischen des Wirkstoffs mit den Hilfsstoffen Maisstärke, Polyvinylpyrrolidon, kolloidale Kieselsäure, mikrokristalline Cellulose sowie Magnesiumstearat, Feuchtgranulieren und Verpressen der homogenen Mischung zu gewölbten Preßlingen von ca. 6,2 mm Durchtesser. Die Kerne der Retardtabletten werden ohne Maisstärke hergestellt, es wird jedoch zusätzlich Zitronensäure zugegeben. Für die Initialtabletten (pro Einheit je zwei) stellt man Preßlinge mit 50 mg Wirkstoff her und überzieht sie mit einem in wäßrigem Medium schnell zerfallenden Überzug aus Hydroxypropylmethylcellulose (20-90 $) und Polyäthylenglykol (0-80 %). Anschließend wird getrocknet.The following example explains the invention without restricting it: example Quinidine sulfate retard form The manufacture of the easily disintegrating initial tablets takes place by mixing the active ingredient with the excipients corn starch, polyvinylpyrrolidone, colloidal silica, microcrystalline cellulose and magnesium stearate, wet granulation and compressing the homogeneous mixture to form domed compacts of approximately 6.2 mm in diameter. The cores of the prolonged-release tablets are made without cornstarch, but it is citric acid was also added. For the initial tablets (two per unit) one produces pellets with 50 mg of active ingredient and covers them with an in aqueous Medium rapidly disintegrating coating of hydroxypropylmethylcellulose ($ 20-90) and Polyethylene glycol (0-80%). Then it is dried.

Des weiteren werden pro Einheit vier Retardtabletten hergestel).t. Sie enthalten ebenfalls jeweils 50 mg Wirkstoff und werden mittels einer üblichen Sprühpistole mit einer Sprühlösung überzogen, die folgende Zusammensetzung aufweist.In addition, four prolonged-release tablets are produced per unit. They also contain 50 mg of active ingredient each and are made using a customary Spray gun coated with a spray solution having the following composition.

Äthylcellulose 14 14 6 Teile Polyäthylenglykol 6000 4 Teile Äthanol (vergällt) 45 Teile Methylenchlorid 45 Teile Für die verwendete Verzögerungsstufe wird eine Lackmenge vorn 5 mg aufgetragen. Anschließend werden die Filmtabletten getrocknet.Ethyl cellulose 14 14 6 parts of polyethylene glycol 6000 4 parts of ethanol (denatured) 45 parts of methylene chloride 45 parts for the delay stage used an amount of varnish is applied in front of 5 mg. Then the film-coated tablets dried.

Als letzter Schritt folgt das Einkapseln der zwei Initialtabletten zusammen mit vier Retardtabletten der hergestellten Verzögerungsstufe in Hartgelatine-Steckkapseln mittels einer Kapselfüllmaschine.The last step is to encapsulate the two initial tablets together with four prolonged-release tablets of the prepared delay stage in hard gelatine capsules by means of a capsule filling machine.

Claims (8)

Patentansprüche 1. Neue Chinidin-Retardform, bei welcher in einer Kapsel Retardtabletten verschiedener Verzögerungsstufen sowie gegebenenfalls unverzögerte Tabletten zu einer Einheit zusammengefaßt sind, dadurch gekennzeichnet, daß die Retardtabletten unter Standardbedindungen mit einer Hülle von 5-30 °% Gewicht, bezogen auf das Gewicht der Tablettenkerne überzogen sind, welche aus 20-90 ? atnylcellulose und 10-80 , Polyätilylenglykol besteht. Claims 1. New quinidine retard form, in which in a Capsule prolonged-release tablets of various delay levels and, if necessary, instantaneous Tablets are combined into a unit, characterized in that the Extended-release tablets under standard conditions with an envelope of 5-30 °% weight, based on on the weight of the tablet cores are coated, which ones from 20-90? atnyl cellulose and 10-80, polyethylene glycol. 2. Retardform nach Anspruch 1, dadurch gekennzeichnet, daß die Gesamt-Wirkstoffdosis zwischen 150 und 1500 mg liegt. 2. Retard form according to claim 1, characterized in that the total dose of active ingredient is between 150 and 1500 mg. 3. Retardform nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß die Hülle der Retardtabletten aus 40-70 % Äthylcellulose und 30-60 % Polyäthylenglykol besteht. 3. Retard form according to one of the preceding claims, characterized in that that the shell of the prolonged-release tablets made of 40-70% ethyl cellulose and 30-60% polyethylene glycol consists. 4. Retardform nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß den Kernen der Retardtabletten sauer reagierende Stoffe zugesetzt worden sind. 4. Retard form according to one of the preceding claims, characterized in that that acidic substances have been added to the cores of the prolonged-release tablets. 5. Retardform nach Anspruch 1, dadurch gekennzeichnet, daß sie zusätzlich eine weitere Initialtablette mit einem physiologisch mit Chinidin zusammenwirkenden Stoff enthält. 5. Retard form according to claim 1, characterized in that it additionally Another initial tablet with a physiologically interacting with quinidine Contains substance. 6. Verfahren zur Herstellung einer neuen Chinidin-Retardform nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß man beim Auftragen der Hülle den Wassergehalt der verwendeten Sprühlösung standardisiert.6. Process for the production of a new quinidine retard form according to One of the preceding claims, characterized in that when applying the shell standardized the water content of the spray solution used. 7. Verfahren zur Herstellung einer neuen Chinidin-Retardform nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß man beim Auftragen der Hülle eine hohe Sprühgeschwindigkeit sowie erhöhte Sprühtemperatur anwendet.7. Process for the production of a new form of sustained-release quinidine One of the preceding claims, characterized in that when applying the shell uses a high spray speed as well as an increased spray temperature. 8. Verfahren zur Herstellung einer neuen Retardform nach Anspruch 5, dadurch gekennzeichnet, daß man bei der Herstellung der Kerne der Retardtabletten sauer reagierende Stoffe einsetzt.8. A method for producing a new sustained-release form according to claim 5, characterized in that in the manufacture of the cores of the prolonged-release tablets uses acidic reacting substances.
DE19782836419 1978-07-15 1978-08-19 Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer Withdrawn DE2836419A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE19782836419 DE2836419A1 (en) 1978-08-19 1978-08-19 Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer
DD79214300A DD146547A5 (en) 1978-07-15 1979-07-12 MEDICINAL RETARDANT SHAPE WITH UNFORGETTABLE POROESEN DIFFUSION SHELLS
NL7905484A NL7905484A (en) 1978-07-15 1979-07-13 MEDICINE WITH DELAYED DELIVERY WITH INSOLUBLE POROUS DIFFUSION COVERS.
ZA00793542A ZA793542B (en) 1978-07-15 1979-07-13 Pharmaceutical preparations
NO792335A NO792335L (en) 1978-07-15 1979-07-13 PHARMACEUTICAL RETARD FORM WITH INSULABLE, POROUS DIFFUSION COATERS
BE0/196306A BE877706A (en) 1978-07-15 1979-07-13 DELAYED DRUG FORM COMPRISING AN INSOLUBLE POROUS BROADCASTING ENVELOPE
DK296979A DK296979A (en) 1978-07-15 1979-07-13 RETARDED RELEASE MEDICINE
GB7924504A GB2025227B (en) 1978-07-15 1979-07-13 Pharmaceutical preparations in retard form
GR59598A GR71195B (en) 1978-07-15 1979-07-13
LU81503A LU81503A1 (en) 1978-07-15 1979-07-13 MEDICINAL PRODUCT RETARD FORM WITH INSOLUBLE POROUS DIFFUSION CASES
IT49752/79A IT1116877B (en) 1978-07-15 1979-07-13 PHARMACEUTICAL FORM FOR DELAYED DELIVERY OF MEDICINAL SUBSTANCES WITH INSOLUBLE POROUS SHELL AND HYDRATION PROCEDURE
FI792204A FI792204A (en) 1978-07-15 1979-07-13 RETARD DOSERINGSFORM FOER CEILING MODEL MED EN LOESLIGT POROEST DIFFUSIONSSKAL
PT69922A PT69922A (en) 1978-07-15 1979-07-13 MEDICAMENT RETARD FORM WITH UNLIMITED POROSEN DIFFUSION ZIPS
SE7906119A SE7906119L (en) 1978-07-15 1979-07-13 TOXIC RETARD FORM WITH INSULABLE POROSA DIFFUSION WRAP
PL21711379A PL217113A1 (en) 1978-07-15 1979-07-13
IL57796A IL57796A0 (en) 1978-07-15 1979-07-13 Pharmaceutical compositions having retarded release of the active substance
FR7918301A FR2430766A1 (en) 1978-07-15 1979-07-13 DELAYED DRUG FORM COMPRISING AN INSOLUBLE POROUS BROADCASTING ENVELOPE
CA331,894A CA1126156A (en) 1978-07-15 1979-07-16 Retard form of pharmaceuticals with insoluble porous diffusion-coats
AU48947/79A AU4894779A (en) 1978-07-15 1979-07-16 Retard compositions
US06/273,643 US4361546A (en) 1978-07-15 1981-06-15 Retard form of pharmaceuticals with insoluble porous diffusion coatings
US06/409,131 US4459279A (en) 1978-07-15 1982-08-18 Retard form of pharmaceuticals with insoluble porous diffusion coatings
US06/604,830 US4578264A (en) 1978-07-15 1984-04-27 Retard form of pharmaceuticals with insoluble porous diffusion coatings

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782836419 DE2836419A1 (en) 1978-08-19 1978-08-19 Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer

Publications (1)

Publication Number Publication Date
DE2836419A1 true DE2836419A1 (en) 1980-02-28

Family

ID=6047491

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19782836419 Withdrawn DE2836419A1 (en) 1978-07-15 1978-08-19 Pharmaceutical preparations in retard form - with active materials in core having semipermeable coating of film former and polymer

Country Status (1)

Country Link
DE (1) DE2836419A1 (en)

Similar Documents

Publication Publication Date Title
DE3850340T2 (en) Numerous small pills in liquid dosage form.
DE69002604T2 (en) Pharmaceutical preparation with delayed release and its manufacture.
LU81503A1 (en) MEDICINAL PRODUCT RETARD FORM WITH INSOLUBLE POROUS DIFFUSION CASES
DE3853566T2 (en) Controlled Release Formulations of Tetracycline Compounds.
DE3587274T2 (en) DOSAGE CONTAINING A VARIETY WITH A DIFFERENTIAL COVERED UNITS.
DE2336218C3 (en) Oral dosage form
DE68907762T2 (en) Medicament preparation with controlled release of active substance and process for its production.
DE2651176C2 (en)
DE69518820T2 (en) Rotogranulate and coating of acetaminophen, pseudoephedrine, chlorpheniramine and, if necessary, dextromethorphan
EP0339506B1 (en) Oral osmotic system with a modified adhesion of the membrane to the core
EP0032562B1 (en) Dipyridamol retard-forms and process for their preparation
DE3811114C2 (en) Two-layer dosage form for the delivery of an active ingredient
DE69619668T2 (en) PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE GAROL-SOLUBLE POLYMER COATING FOR ACTIVE SUBSTANCE DELIVERY IN THE COLON
EP0069259B1 (en) Prolonged-action form of bromohexine, and process for its preparation
DE69101314T2 (en) DOSAGE FORM FOR ADMINISTERING A MEDICINAL PRODUCT TO THE INTESTINATE.
EP0299211B1 (en) Dhp-coated tablet
DE69131880T2 (en) Summaries and their use in the treatment of neurological diseases
DE69020758T2 (en) Coating material that controls drug delivery for long-acting formulations.
DE3633292A1 (en) PHARMACEUTICAL COMPOSITION
DE3050131T1 (en) IMPROVEMENTS TO METHODS FOR PREPARING GALENICAL PREPARATION WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENICAL PREPARATIONS FOR DRUGS OBTAINED THEREBY
DE3915150A1 (en) LONG-ACTING DICLOFENAC SODIUM PRAEPARATION
DE19739031A1 (en) Oral administration agent, its preparation and use
DE1467781A1 (en) Process for the production of coated tablets with extended release of active ingredients
DE3814532A1 (en) DHP-RETARD-PREPARATION
DE60308828T2 (en) Oral pharmaceutical composition with sustained release

Legal Events

Date Code Title Description
OAP Request for examination filed
OD Request for examination
8178 Suspension cancelled
8130 Withdrawal